top of page
Verquvo (vericiguat) is used to decrease the risk of cardiovascular death andheart failurehospitalization in patients who are experiencing symptoms of long-lasting heart failure with an ejection fraction less than 45% and have recently been hospitalized or received IV medications for heart failure. Verquvo is classified as asoluble guanylate cyclase (sGC) stimulator. Fact Table Formula C19H16F2N8O2 License US DailyMed Bioavailability 93% Legal status Rx-Only Chemical Name Vericiguat Elimination half-life 30 hours Dosage (Strength) 2.5mg, 5mg, 10mg Pregnancy Not Recommended Brands Verquvo Protein binding 98% PubChem CID 54674461 MedlinePlus a621014 ChEBI 142432 ATC code C01DX22 DrugBank DB15456 KEGG D11051 Routes of administration By mouth

Verquvo (Vericiguat)

  • Verquvo is available in 2.5 mg, 5 mg, and 10 mg tablets. The recommended initial dose is 2.5 mg by mouth one time a day with food. The tablets can be crushed and mixed with water if you are unable to swallow the tablets whole. Your doctor may change your dose depending on how well you respond to the medication.
bottom of page